Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Indoles
  • Interferon-alpha
  • Kidney Neoplasms
  • Pyrroles

abstract

  • Patients randomised to sunitinib had longer clinical benefit, defined as Q-TWiST scores, than patients randomised to IFN-α.

publication date

  • May 8, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3349250

Digital Object Identifier (DOI)

  • 10.1038/bjc.2012.149

PubMed ID

  • 22568998

Additional Document Info

start page

  • 1587

end page

  • 90

volume

  • 106

number

  • 10